Mechanisms underlying corticosteroid resistance in patients with asthma: a review of current knowledge
- PMID: 37658478
- DOI: 10.1080/17476348.2023.2255124
Mechanisms underlying corticosteroid resistance in patients with asthma: a review of current knowledge
Abstract
Introduction: Corticosteroids are the most cost-effective anti-inflammatory drugs available for the treatment of asthma. Despite their effectiveness, several asthmatic patients have corticosteroid resistance or insensitivity and exhibit a poor response. Corticosteroid insensitivity implies a poor prognosis due to challenges in finding alternative therapeutic options for asthma.
Areas covered: In this review, we describe asthma phenotypes and endotypes, as well as their differential responsiveness to corticosteroids. In addition, we describe the mechanism of action of corticosteroids underlying their regulation of the expression of glucocorticoid receptors (GRs) and their anti-inflammatory effects. Furthermore, we summarize the mechanistic evidence underlying corticosteroid-insensitive asthma, which is mainly related to changes in GR gene expression, structure, and post-transcriptional modifications. Finally, various pharmacological strategies designed to reverse corticosteroid insensitivity are discussed.
Expert opinion: Corticosteroid insensitivity is influenced by the asthma phenotype, endotype, and severity, and serves as an indication for biological therapy. The molecular mechanisms underlying corticosteroid-insensitive asthma have been used to develop targeted therapeutic strategies. However, the lack of clinical trials prevents the clinical application of these treatments.
Keywords: Corticosteroids; asthma; chronic rhinosinusitis with nasal polyposis; corticosteroid resistance; glucocorticoid receptor.
Similar articles
-
Mucin 1 downregulation associates with corticosteroid resistance in chronic rhinosinusitis with nasal polyps.J Allergy Clin Immunol. 2015 Feb;135(2):470-6. doi: 10.1016/j.jaci.2014.07.011. Epub 2014 Aug 23. J Allergy Clin Immunol. 2015. PMID: 25159466
-
Corticosteroids: the drugs to beat.Eur J Pharmacol. 2006 Mar 8;533(1-3):2-14. doi: 10.1016/j.ejphar.2005.12.052. Epub 2006 Jan 24. Eur J Pharmacol. 2006. PMID: 16436275 Review.
-
Pharmacological strategies to regain steroid sensitivity in severe asthma and COPD.Curr Opin Pharmacol. 2019 Jun;46:73-81. doi: 10.1016/j.coph.2019.04.010. Epub 2019 May 9. Curr Opin Pharmacol. 2019. PMID: 31078066 Review.
-
Defects of protein phosphatase 2A causes corticosteroid insensitivity in severe asthma.PLoS One. 2011;6(12):e27627. doi: 10.1371/journal.pone.0027627. Epub 2011 Dec 19. PLoS One. 2011. PMID: 22205926 Free PMC article.
-
Addressing corticosteroid insensitivity in adults with asthma.Expert Rev Respir Med. 2016 Feb;10(2):137-56. doi: 10.1586/17476348.2016.1133304. Epub 2016 Jan 28. Expert Rev Respir Med. 2016. PMID: 26678267
Cited by
-
Supratherapeutic Inhaled Corticosteroid Use in Patients Initiating on Biologic Therapies for Severe Asthma: A Nationwide Cohort Study.Lung. 2025 Mar 11;203(1):42. doi: 10.1007/s00408-025-00796-5. Lung. 2025. PMID: 40069448 Free PMC article.
-
The role of mitochondria in eosinophil function: implications for severe asthma pathogenesis.Front Cell Dev Biol. 2024 Mar 1;12:1360079. doi: 10.3389/fcell.2024.1360079. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 38495619 Free PMC article. Review.
-
C-Phycocyanin Prevents Oxidative Stress, Inflammation, and Lung Remodeling in an Ovalbumin-Induced Rat Asthma Model.Int J Mol Sci. 2024 Jun 27;25(13):7031. doi: 10.3390/ijms25137031. Int J Mol Sci. 2024. PMID: 39000141 Free PMC article.
-
Targeting psoriatic inflammation with natural compounds: mechanistic insights and therapeutic promise.Inflammopharmacology. 2025 Jul;33(7):3843-3870. doi: 10.1007/s10787-025-01851-6. Epub 2025 Jul 21. Inflammopharmacology. 2025. PMID: 40690118 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical